BerGenBio ASA: Increase of share capital, exercise of share options

Report this content

Bergen, Norway, 16 February 2022  

The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company's share capital by NOK 10,507.70 by issuance of 105,277 new shares. The new shares are subscribed for by option owners who wishes and are entitled to exercise options in accordance with the Company's option scheme. Each option gives a right to receive one share in the Company. The subscription price is in accordance with the prevailing options price pursuant to the Company´s option scheme, in average NOK 16.01 per share.


The capital increase is expected to be registered within 7 days, and following the issuance of the new shares, the issued share capital of BerGenBio ASA will be NOK 8,866,053.20 consisting of 88,660,532, each with a par value of NOK 0.10.






Martin Olin

CEO, BerGenBio ASA



Rune Skeie

CFO, BerGenBio ASA


Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



Dokumenter og linker